血脂康在临床应用的安全性
832中国循环杂志 2020年8月 第35卷 第8期（总第266期）Chinese Circulation Journal，August，2020，Vol. 35 No.8（Serial No.266）
分析[J]. 临床心血管病杂志, 2014, 30(9): 752-754. DOI: 10. 13201/j.
issn. 1001-1439. 2014. 09. 004.
[22] Venero CV, Venero JV, Wortham DC, et al. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins[J]. Am J Cardiol,
2010, 105(5): 664-666. DOI: 10. 1016/j. amjcard. 2009. 10. 045.
[23] Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast
rice (2, 400 mg twice daily) versus pravastatin (20 mg twice daily)
in patients with previous statin intolerance[J]. Am J Cardiol, 2010,
5(2): 198-204. DOI: 10. 1016/j. amjcard. 2009. 08. 672.
[24] Cui F, Zhang Y, Wei Q , et al. A novel medical treatment for lipid control in patients with unstable angina pectoris and statin-induced
liver dysfunction[J]. Acta Cardiol Sin, 2015, 31(1): 66-71. DOI: 10.
6515/acs20140721b.
[25] 中国老年学和老年医学学会心脑血管病专业委员会, 血脂康(胶囊)临床应用中国专家共识组. 血脂康(胶囊)临床应用中国专家共识(2017修订版)[J]. 中华内科杂志, 2018, 57(2): 97-100. DOI:
10. 3760/cma. j. issn. 0578-1426. 2018. 02. 003.
[26] Li JJ, Lu ZL, Kou WR, et al. Impact of long-term Xuezhikang
therapy on cardiovascular events in high-risk patients with
nonspecific, preexisting abnormal liver tests: a post-hoc analysis from Chinese Coronary Secondary Prevention Study (CCSPS)[J]. Int
J Cardiol, 2012, 154(3): 362-365. DOI: 10. 1016/j. ijcard. 2011. 11.
005.
[27] 王明毅, 张宇静, 徐键, 等. 血脂康与氟伐他汀对轻度肝功能异
常老年心绞痛患者的安全性比较[J]. 中国基层医药, 2015, 22(6):
851-853. DOI: 10. 3760/cma. j. issn. 1008-6706. 2015. 06. 017.
[28] 邹广东, 毕丽丽, 可立志, 等. 血脂康治疗828 例脂肪肝的疗效及B 超声像图变化[J]. 全科临床荟萃, 2004, 7(8): 582. DOI : 10. 3969/j. issn. 1007-9572. 2004. 08. 045.
（收稿日期: 2020-04-24）
（编辑: 卢芳）[13] Moriarty PM, Roth EM, Karns A, et al. Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study[J]. J Clin Lipidol, 2014, 8(6): 568-575. DOI: 10. 1016/j. jacl. 2014. 09. 002. [14] 杜保民, 陆宗良, 陈祚, 等. 血脂康对合并高血压患者的冠心病二级预防作用[J]. 中华心血管病杂志, 2006, 34(10): 890-894. DOI: 10. 3760/j: issn: 0253-3758. 2006. 10. 007. [15] Li JJ, Lu ZL, Kou WR, et al. Long-term effects of Xuezhikang on blood pressure in hypertensive patients with previous myocardial infarction: data from the Chinese Coronary Secondary Prevention Study (CCSPS)[J]. Clin Exp Hypertens, 2010, 32(8): 491-498. DOI: 10. 3109/10641961003686427. [16] Zhao SP, Lu ZL, Du BM, et al. Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS)[J]. J Cardiovasc Pharmacol, 2007, 49(2): 81-84. DOI: 10. 1097/FJC. 0b013e31802d3a58. [17] 徐智超, 唐海沁, 张亚文, 等. 血脂康与他汀类药物调脂效果对比及安全性分析[J]. 中国临床保健杂志, 2017, 20(1): 28-32. DOI : 10. 3969/J. issn. 1672-6790. 2017. 01. 010. [18] 王彩玲, 李曙远, 张伟. 血脂康对2型糖尿病人胰岛素敏感性的影响[J]. 中国糖尿病杂志, 2001, 9(3): 171-173. [19] 孙美珍, 田林华, 迟家敏. 血脂康对II 型糖尿病糖、脂代谢的影响[J]. 中华内科杂志, 1998, 137(6): 364-366. [20] Ye P, Lu ZL, Du BM, et al. Effect of Xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China coronary secondary prevention study[J]. J Am Geriatr Soc, 2007, 55(7): 1015-1022. DOI: 10. 1111/j. 1532-5415. 2007. 01230. x. [21] 江成功, 郑琴, 刘梅林, 等. 老年患者服用血脂康的疗效与安全性